Lexaria Bioscience Signs CRO Contracts for New GLP-1 Human Study

• Lexaria Bioscience Corp. has signed contracts with a CRO to conduct Human Pilot Study #7 (GLP-1-H26-7)evaluating oral GLP-1 formulations.

• The study aims to build on prior safety and tolerability data while comparing performance to existing GLP-1 therapies. 

Lexaria Bioscience Corp. announced it has signed contracts with a contract research organization (CRO) to begin Human Pilot Study #7 (GLP-1-H26-7), evaluating oral DehydraTECH-processed GLP-1 formulations. The study represents the latest step in the company’s clinical development program focused on oral alternatives to injectable GLP-1 therapies used in obesity and diabetes treatment. 

The new human trial is expected to evaluate two oral DehydraTECH-semaglutide formulations and compare them against existing GLP-1 therapies. The study is designed to assess pharmacokinetics, safety, tolerability, and overall clinical performance of the company’s oral drug delivery technology. 

Lexaria indicated that contracts with the CRO have been finalized and submissions are being prepared for ethics approval from an independent review board before study initiation. The company said this regulatory process represents the final step prior to dosing in the new human clinical trial. 

The study builds on prior Lexaria GLP-1 clinical programs, where DehydraTECH-enabled formulations demonstrated improved tolerability and reduced side effects compared with existing oral GLP-1 therapies. The company said the new study aims to preserve these safety advantages while maintaining competitive pharmacokinetic performance. 

“We hope to preserve the superior safety and tolerability profiles observed in prior GLP-1 studies while achieving pharmacokinetic performance that matches or exceeds existing oral GLP-1 therapies.”

Chris Bunka, Chief Executive Officer of Lexaria Bioscience